Marinomed Biotech AG announces clinical trial at Swansea University Medical School to investigate efficacy of Carragelose in preventing COVID-19

▴ Marinomed Biotech AG announces clinical trial at Swansea University Medical School to investigate efficacy of Carragelose in preventing COVID-19
Objective of the study is to assess the efficacy of Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections

Marinomed Biotech AG, a globally operating biopharmaceutical company, is pleased to announce recently that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID).

The investigator-initiated trial at Swansea will be recruiting 480 healthcare professionals managing COVID-19 patients during the pandemic. Objective of the study is to assess the efficacy of Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections. Further endpoints include infection with other respiratory viruses, usability of the spray for prophylaxis and the effects on quality adjusted life years (QALYs). The ongoing clinical trial is supported by Marinomed Biotech AG, the originator and licensor of Carragelose and Boots UK; the Carragelose nasal spray used in the study is marketed as Boots Dual Defence in the United Kingdom.

The design of the double-blind trial is finalized and planned to start shortly. The study population will be equally randomized into a treatment group (0.12 mg/ml iota-carrageenan / 0.4 mg/ml kappa-carrageenan in 0.5% saline) and a placebo group (0.5 % saline) and will apply this study regime three times a day, one dose into each nostril and three throat sprays, over the course of eight weeks .

“With the world in the devastating grip of this SARS-CoV2 pandemic and nurses and doctors especially exposed, we are looking forward to this very important clinical data from the Swansea trial. Our pivotal clinical data for Carragelose demonstrated alleviation of different coronavirus infections. Marinomed has been able to show neutralizing activity towards the new coronavirus in vitro earlier this year.” said Dr Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. Adding, “We have very good reason to expect and hope that the trial will confirm our in vitro findings and contribute to validating Carragelose nasal spray as a COVID-19 prophylaxis for the vulnerable community of healthcare professionals, protecting them from contracting COVID-19 infections.”

“After seeing the effects of this pandemic on colleagues caring for patients with COVID-19, we wanted to find a way for research to help protect frontline NHS staff,” said Dr. Zita Jessop, Principal Investigator for the clinical trial and clinician scientist at Swansea University. “Previous studies highlighted the effectiveness of iota-carrageenan-based nasal sprays against coronaviruses, indicating promise against SARS-CoV-2. If the results of this randomised placebo-controlled clinical trial are positive as we expect, this has the potential to add an extra prevention strategy in the fight against COVID-19,” she added.

Tags : #MarinomedBiotechAG #LatestNewsonMarinomedBiotechAG1stDec #LatestPharmaNews1stDec #LatestNewsonCOVID1stDec #UnitedKingdom

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

A New Dawn for Eye Health in Obesity: How Bariatric Surgery Repairs Early Eye DamageDecember 14, 2024
Healing Invisible Wounds: How Indian Government’s Bold Initiatives Are Tackling the Mental Health CrisisDecember 14, 2024
The 8-Hour Miracle: Here’s How Doctors Rewrote a Young Girl’s FateDecember 14, 2024
University of Manchester invites applications for MSc Climate Change: Science, Society and Solutions December 13, 2024
Pollution vs. Population: Can India Survive Its Toxic Air?December 13, 2024
New Milestone: First Cryopreserved Stem Cell Donation Helps Blood Cancer Patient December 13, 2024
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in MacauDecember 13, 2024
Plastic Pollution Goes Personal: Microplastics Found in Human BloodDecember 12, 2024
The Fat-Fuelled Weapon Against Cancer: How the Keto Lifestyle is Redefining Cancer TherapyDecember 12, 2024
Gene Therapy in India: How Indian Scientists Redefined Hemophilia TreatmentDecember 12, 2024
Empowering India’s Workforce: FinX Raises $6M from Elevar Equity to revolutionise employability in the BFSI IndustryDecember 12, 2024
India’s Win Over Malaria: A Global Health Victory in ProgressDecember 11, 2024
TB-Free India by 2025: Bold Vision or Achievable Reality?December 11, 2024
Aakash Healthcare Supports the 14th Special Athletic Meet for Children with Special NeedsDecember 11, 2024
The University of Manchester invites applications for an MSc in International Disaster ManagementDecember 10, 2024
Preventing Mother-to-Child HIV Transmission: Strategies and ImportanceDecember 10, 2024
USIBC Signs MOU with Government of Telangana, Hosts AI and GCC Industry RoundtableDecember 10, 2024
CarDekho Group’s New Auto Segment’s Shift in Fuel Preferences Report: Electric Vehicles (EVs) Lead the Chart with 26% YoY Traffic Increase December 10, 2024
India’s leading eCommerce enablement platform Shiprocket appoints industry veteran Vivek Sharma as VP of International ShippingDecember 10, 2024
Failure to find all TB cases defeats us in #endTB effortsDecember 10, 2024